Ulas, A. Et Al. 2015. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.. Asian Pacific journal of cancer prevention : APJCP , vol.16 , 1643-9.

Ulas, A., Kos, T., Avci, N., Cubukcu, E., Olmez, O. F., Bulut, N., ... Degirmenci, M.(2015). Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.. Asian Pacific journal of cancer prevention : APJCP , vol.16, 1643-9.

Ulas, Arife Et Al. "Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.," Asian Pacific journal of cancer prevention : APJCP , vol.16, 1643-9, 2015

Ulas, Arife Et Al. "Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.." Asian Pacific journal of cancer prevention : APJCP , vol.16, pp.1643-9, 2015

Ulas, A. Et Al. (2015) . "Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.." Asian Pacific journal of cancer prevention : APJCP , vol.16, pp.1643-9.

@article{article, author={Arife Ulas Et Al. }, title={Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.}, journal={Asian Pacific journal of cancer prevention : APJCP}, year=2015, pages={1643-9} }